Verteporfin therapy in Age-related Macular Degeneration (VAM): An open-label multicenter photodynamic therapy study of 4,435 patients

Retina

Volumn 24, Issue 4, 2004, Pages 512-520

  Bressler, Neil M ^a,b,c  

^a VAM Study Writing Committee   (United States)

^b Building 118 ^*  (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Photodynamic therapy; Verteporfin; Visudyne

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; CANADA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG SAFETY; DYSPNEA; EXTRAVASATION; EYE PAIN; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INJECTION PAIN; INJURY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PNEUMONIA; RETINA MACULA AGE RELATED DEGENERATION; SELF REPORT; SUBRETINAL NEOVASCULARIZATION; UNITED STATES; VISUAL ACUITY; VISUAL DISORDER;

EID: 4043175710     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200408000-00003     Document Type: Article

References (9)

1. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials-TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.
2. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 2001;119:198-207.
3. Verteporfin In Photodynamic therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP Report No. 1. Ophthalmology 2001;108:841-852.
4. Verteporfin In Photodynamic therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-560.
5. Treatment of Age-related Macular Degeneration with Photodynamic therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials-Treatment of Age-related Macular Degeneration with Photodynamic Therapy and Verteporfin In Photodynamic Therapy Report No. 4. Retina 2004 (in press).
6. Borodocker N, Spaide RF, Maranan L, et al. Verteporfin infusion associated pain. Am J Ophthalmol 2002;133:211-214.
7. Spaide RF, Maranan L. Neutrophil margination as a possible mechanism for verteporfin infusion associated pain. Am J Ophthalmol 2003;135:549-550.
8. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP Report No. 5. Arch Ophthalmol 2002;120:1307-1314.
9. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-1173.